Active, Not Recruiting
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
NCT04622319
- Conditions
- HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
- Locations
-
- The Oncology Institute of Hope & Innovation Anaheim, California, United States
- Kaiser Permanente Anaheim, California, United States
- Kaiser Permanente Baldwin Park, California, United States
- Kaiser Permanente Bellflower, California, United States